| A
FOURTEEN-YEAR REVIEW OF RADICAL CYSTECTOMY FOR TRANSITIONAL CELL CARCINOMA
DEMONSTRATING THE USEFULNESS OF THE CONCEPT OF LYMPH NODE DENSITY
(
Download pdf )
CHI W. CHENG, CHI
F. NG, CHI K. CHAN, WAI S. WONG, PUN E. HUI, YIM F. WONG
Department
of Surgery and Department of Clinical Oncology, The Chinese University
of Hong Kong, Prince of Wales Hospital, Hong Kong, China
ABSTRACT
Objective:
We studied the long-term outcome of radical cystectomy for transitional
cell carcinoma and evaluated prognostic factors for disease specific survival.
Materials and Methods: A retrospective review
was carried out for all cystectomies performed for transitional cell carcinoma
between 1989 and 2002. Disease specific survival was correlated to patient,
pathological and operative factors as well as to adjuvant therapy.
Results: Of the 133 cystectomies included,
100 were male and 33 were female patients. The median age was 69 years
(range 43 to 86). The median follow up was 20 months (range 0 to 158).
With univariate analysis, pT stage, N stage, lymph node density, carcinoma
in-situ, surgical margin and post-operative radiotherapy to distant metastasis
were predictive of disease specific survival. On the other hand, with
multivariate analysis, only pT stage, lymph node density and post-operative
radiotherapy to distant metastasis were predictive of disease specific
survival. Within the group of node positive disease, lymph node density
also predicted disease specific survival with both univariate and multivariate
analyses. Patients with lymph node density 20% or below showed better
disease specific survival.
Conclusions: pT stage and lymph node density
were found to be the most important predictive factors for disease specific
survival after cystectomy in the Asian population.
Key
words: bladder; carcinoma, transitional cell; cystectomy; lymph
nodes
Int Braz J Urol. 2006; 32: 536-49
INTRODUCTION
Radical
cystectomy is the standard surgical treatment for muscle invasive bladder
transitional cell carcinoma (TCC) and can achieve good long term results
for organ confined disease. Patients with locally advanced or nodal disease
may also benefit from the surgery (1-3). pT staging and N staging have
been widely accepted as important prognostic factors. Both the value and
the extent of pelvic lymphadenectomy have been controversial. Lymph node
density (LND), defined as the percentage of resected lymph nodes that
were involved and calculated by the division of the number of lymph nodes
involved by the number resected, has also been found to be a useful prognostic
variable (4). A retrospective review of radical cystectomy was carried
out to evaluate prognostic factors including the LND to see if they were
also applicable to the Asian population.
MATERIALS
AND METHODS
Radical
cystectomy performed in the Prince of Wales Hospital for TCC between 1989
and 2002 were reviewed. Cystectomy was preceded by bilateral pelvic lymphadenectomy
with the two specimens sent separately and followed by either an ileal
conduit or a continent diversion. The boundaries of the pelvic lymphadenectomy
were the muscle pelvic side wall laterally, vesical fascia medially, lateral
border of external iliac vein superiorly, obturator nerve inferiorly,
bifurcation of the common iliac artery proximally and femoral canal inferiorly.
Patients with bulky tumors might receive
radical radiotherapy (RT) before salvage cystectomy. Younger patients
with good renal function might receive neoadjuvant systemic chemotherapy
before radical cystectomy at the discretion of the urologists. Patients
with positive pelvic lymph nodes or minimal or positive surgical margins
might receive post-operative RT to the pelvis. Patients with recurrence
as distant metastases might receive post-operative systemic chemotherapy
or post-operative RT to the metastases at the discretion of the oncologists.
Data were collected from patient case notes,
patient or family telephone contact and electronic medical records, including
patient (age, sex, mode of presentation), pathological (pT stage, N stage,
number of nodes involved, number of nodes resected, LND, grading, coexistence
of carcinoma in-situ or CIS, surgical margin) and operative factors (continent
diversion, simultaneous nephrectomy, simultaneous urethrectomy) as well
as adjuvant therapy (RT, chemotherapy). The staging system employed was
the 2002 American Joint Committee on Cancer TNM staging system. In cases
of mixed stages or grades, the highest stage or grade was documented.
Presentation mode could either be progression from superficial disease
or de novo muscle invasive. LND was defined as stated above. A positive
surgical margin means a positive one confirmed microscopically and a minimal
margin dictates that cancer cells are found 1 mm or less close to the
surgical margin.
End points recorded included recurrence
and death. The time to first recurrence, the survival and the cause of
death were documented. Recurrence free interval and patient survival were
defined as the time from cystectomy to the end point (recurrence, death
or censored). In the analysis of disease specific survival, patients who
died of TCC were classified as deaths.
The Kaplan-Meier method was used to calculate
the survival curves. The log rank test and the Cox proportional hazards
model were used for univariate and multivariate analyses respectively,
to assess the influence on the survival curves by patient, pathological
and operative factors as well as adjuvant therapy. Logistic regression
was used to assess the influence on LND by pre-operative and intra-operative
parameters.
RESULTS
Clinico-pathological
Features
One hundred and forty four cystectomies
were performed in the 14 year period. Eleven cases were excluded from
this review because of histology other than TCC (seven cases of adenocarcinoma,
one case of squamous cell carcinoma, one case of leiomyosarcoma and two
cases of carcinosarcoma). There were 100 males and 33 females. The mean
and median ages were 67.1 and 69 years (range 43 to 86), respectively.
The indications for radical cystectomy were
mainly muscle invasive disease (123 cases) except one case of CIS resistant
to treatment and nine cases of recurrent pT1 disease. The details of histological
findings were shown in Table-1. Reconstruction was achieved by ileal conduit
in 112 cases and continent diversion in 21 cases. Continent diversion
performed included 19 ileal neobladders, one Indiana pouch and one right
colonic pouch. Nine patients had a simultaneous nephrectomy (three cases
for simultaneous upper tract TCC and six cases for non-functioning kidneys)
and 25 patients had a simultaneous urethrectomy. Lymph node status was
unknown in thirteen patients, otherwise, thirty eight patients (38/120
= 31.7%) showed positive lymph nodes. The mean and median numbers of nodes
resected for the whole series was 9.48 and eight, respectively (range
1 to 49) while the mean and median numbers of nodes involved was 0.93
and zero, respectively (range 0 to 13). On the other hand, the mean and
median numbers of nodes resected for node positive cases was 9.62 and
seven, respectively (range 1 to 49) while the mean and median numbers
of nodes involved was 2.95 and two, respectively (range 1 to 13). In patients
free of nodal disease, the mean and median numbers of nodes resected were
9.65 and eight, respectively (range 1 to 33).
The distribution of various pathological
subgroups was as follows: 7.5% were superficial lymph node negative, 35%
were muscle invasive lymph node negative, 25.8% were extravesical lymph
node negative and 31.7% were lymph node positive disease. Moreover, the
incidence of nodal involvement in various pT stages was found to be 11.1%
in pT1, 16.0% in pT2, 43.6% in T3 and 57.1% in T4.
The number of cases that received RT and
chemotherapy are shown in Table-2.
Endpoints
Sixty one cases recurred at a median surveillance
of 15 months (range 0 to 158). The median time to recurrence was nine
months (range 0 to 67). Four cases recurred locally while the remaining
57 recurred as distant metastases.
Eighty four cases died being 68 of cancer
at a median follow up of 20 months (range 0 to 158). Five cases of perioperative
mortality (5/133 = 3.8%) within 30 days of cystectomy were also classified
as cancer, as they died as a result of a procedure for the disease. The
median time to cancer death was 13.5 months (range 0 to 118).
The 1,3,5 and 10-year overall survival were
69.5%, 47.4%, 37.2% and 25.2%, while the corresponding disease specific
survival were 74.1%, 53.7%, 42.2% and 34.6%. The corresponding survival
curves were shown in Figure-1.
The 5 and 10-year disease specific survival
for various pathological subgroups were as follows: 71.4% and 35.7% for
superficial lymph node negative, 72.7% and 61.5% for muscle invasive lymph
node negative, 19.9% and 19.9% for extravesical lymph node negative and
28.7% and 28.7% for lymph node positive disease.
Prognostic
Factors
With univariate analysis, pT staging, N
staging, LND, CIS, surgical margin and post-operative RT to distant metastasis
were predictive of disease specific survival. With multivariate analysis,
only pT staging, LND and post-operative RT to distant metastasis were
predictive of disease specific survival.
The disease specific survival curves defined
by those factors predictive of disease specific survival were shown from
Figures-2 to 7. The results of univariate and multivariate analyses on
disease specific survival for all factors were summarized in Table-3.
The disease specific survival curves for various pT stages were shown
in Figure-2. The 5-year survival for pT1, pT2, pT3 and pT4 disease were
71.4%, 69.1%, 17.2% and 12.2%, respectively (log rank, p < 0.0001).
The disease specific survival curves for various N stages were shown in
Figure-3. The 5-year survival for N0,N1,N2, and N3 disease were 52.2%,
61.0%, 17.8% and 0%, respectively (log rank, p = 0.0003). Similarly to
what had been previously reported in literature, we also found a division
line on LND at 20% discriminated patients into two groups with respect
to disease specific survival (log rank, p < 0.0001). The disease specific
survival curves for LND of 20% or less and LND more than 20% were shown
in Figure-4. 54.0% of patients with LND of 20% or less survived five years
or more, whereas all patients with LND more than 20% were either dead
or censored at 39 months. The disease specific survival by surgical margin
was shown in Figure-5. The 5-year disease specific survival for a clear,
minimal or positive margin was 52.3%, 8.3% and 0% respectively (log rank,
p < 0.0001). The disease specific survival by presence or absence of
CIS was shown in Figure-6. The 5-year disease specific survival was 37.9%
without CIS and 64.9% with CIS (log rank, p = 0.0417). The disease specific
survival by post-operative RT to distant metastasis was shown in Figure-7.
The 5-year disease specific survival was 51.9% without post-operative
RT to distant metastasis and 0% with post-operative RT to distant metastasis
(log rank, p = 0.0001).
Within the group of node positive disease,
we also found a division line on LND at 20% discriminated patients into
two groups with respect to disease specific survival (log rank, p = 0.0003).
LND of 20% predicted disease specific survival with both univariate and
multivariate analyses. The disease specific survival curves for LND of
20% or less and LND more than 20% in patients with nodal disease were
shown in Figure-8. 64.3% of patients with LND of 20% or less survived
five years or more, whereas all patients with LND more than 20% were either
dead or censored at 39 months. Furthermore, in this group of node positive
patients, neither the pT stage nor the number of nodes involved or resected,
affected the disease specific survival in multivariate analysis.
We also analyzed by logistic regression
the effects on LND (cut off point at 20%) by pre-operative and intra-operative
factors to see if LND could be predicted before proceeding with cystectomy.
These factors included sex, age, presentation mode, pT stage, grading,
CIS, number of nodes resected, pre-operative RT, pre-operative chemotherapy,
continent diversion, simultaneous nephrectomy and simultaneous urethrectomy.
However, no such factor was found to predict LND in our series.
COMMENTS
This
is a retrospective review with a relatively small sample size and short
follow up period than similar review in the literature. It is a heterogeneous
group of patients as those receiving chemotherapy and RT were also included.
The long recruiting period might involve variations in surgical techniques
and treatment approach. Moreover, the number of lymph nodes resected in
this review was also small. In order to achieve improvement in survival,
Herr (4) observed that at least eight and nine lymph nodes should be removed,
in node negative and positive patients, respectively. The corresponding
figures in our series were respectively eight and seven,. Despite these
weaknesses, several prognostic factors, and in particular LND, were found
to be predictive of disease specific survival.
An important finding was that N staging
affected disease specific survival in univariate analysis but was replaced
by LND in multivariate analysis. Moreover, neither the number of nodes
involved nor the number resected affected survival in multivariate analysis.
This implies that the concept of surgical margin can also be applied to
the lymph node status, and residual disease in the lymph nodes should
be avoided. This can be accomplished by a more extensive lymphadenectomy
to include clinically undetected lymph node micrometastases and to reduce
the LND. However, randomized trials comparing extended and standard lymphadenectomy
are needed before concluding that extended lymphadenectomy improves disease
specific survival.
The value and extent of pelvic lymphadenectomy
during cystectomy were considered controversial in the eighties. Though
complete pelvic lymphadenectomy was advocated by some authors (5), others
concluded that its contribution to survival was minimal (6,7). There were
also proponents of a more limited dissection of pelvic lymph nodes (8).
The pendulum swung to the side for meticulous pelvic lymphadenectomy in
the nineties (9-11). At the turn of the millennium, data on its morbidity
(12) and lymphatic mapping (13-16) were evolving, together with other
related concepts like sentinel nodes (15) and LND (4).
Stein (17) introduced the term LND though
the concept had been previously mentioned by Herr (18) and Konety (19).
He reported that for patients with nodal disease, those with a LND of
20% or less had a 10-year recurrence free survival of 43%, compared to
17% of those with LND more than 20%. We also found in our study that a
division line on LND at 20% discriminated patients with nodal disease
into two groups with respect to disease specific survival, with both univariate
and multivariate analyses. Sixty four point three percent of those with
LND of 20% or less survived ten years or more, whereas all patients with
LND more than 20% were either dead or censored at 39 months (Figure-8).
Our data showed that LND was a useful prognostic
factor supplementary to N stage for disease specific survival. Future
studies are needed before LND can be considered a widely accepted staging
system or even used to replace the N staging. Moreover, the technique
of lymphadenectomy, the way of counting the lymph nodes and the histological
assessment should be standardized. Lymph node mapping studies (13-16)
may facilitate extensive lymphadenectomy allowing, for example, one level
higher resection.
Knowing that LND plays a crucial role in
determining survival, it is important to define what pre-operative and
intra-operative factors will predict LND. This will help to decrease the
number of unnecessary cystectomy that will not offer advantage on disease
specific survival. We analyzed by logistic regression the effects on LND
by several pre-operative and intra-operative factors mentioned above.
However, no such factor was found to predict LND in our series.
Our data showed that pT staging affected
disease specific survival in univariate and multivariate analyses. This
agreed with findings of other series in the literature and our survival
figures were comparable to them (1). The marked difference in survival
between pT2 and pT3 diseases as shown in Figure-2 may suggest that a more
aggressive adjuvant approach should be adopted for extravesical disease.
Other factors that predicted disease specific
survival in our series included post-operative RT to distant metastasis,
surgical margin and CIS. Post-operative RT to distant metastasis also
adversely affected survival in univariate and multivariate analyses. However,
this might simply imply that those that developed metastases and hence
received palliative RT died earlier. A minimal or positive surgical margin
was shown to affect survival only in univariate but not in multivariate
analysis. This might be because the influence of surgical margin could
be explained by other factors such as pT staging, for example. The paradoxical
finding of higher disease specific survival associated to CIS just reached
statistical significance with univariate analysis (log rank, p = 0.0417)
and not with multivariate analysis.
We also specifically analyzed the effects
of pre-operative and post-operative adjuvant therapy. Our results showed
that chemotherapy did not alter the survival at all. Raghavan (20) pointed
out that multi-center randomized trials had shown survival benefit from
neoadjuvant chemotherapy while adjuvant chemotherapy failed to show such
benefit. Similarly, our results showed that pre-operative RT to the bladder
or post-operative RT to the pelvis did not alter the survival. In this
regard, a meta-analysis by Shelley (21) showed a survival benefit with
pre-operative RT plus radical cystectomy when compared to radical RT plus
salvage cystectomy. As mentioned above, our finding that post-operative
RT to distant metastasis predicted survival might simply imply that those
who developed metastases died earlier.
CONCLUSIONS
In
this retrospective review of radical cystectomy performed for TCC, pT
stage, N stage, LND, CIS, surgical margin and post-operative RT to distant
metastasis were found to predict disease specific survival. In particular,
LND of 20% discriminated patients into two groups with respect to disease
specific survival. The concept of LND may be useful in future staging
systems and it shed a light on the importance of extended lymphadenectomy.
This review of 133 patients failed to define any pre-operative and intra-operative
factors that could predict LND. Future studies of larger scale may make
this possible so as to decrease the number of unnecessary cystectomy that
will not offer advantage on disease specific survival.
CONFLICT
OF INTEREST
None
declared.
REFERENCES
- Frazier HA, Robertson JE, Dodge RK, Paulson DF: The value of pathologic
factors in predicting cancer-specific survival among patients treated
with radical cystectomy for transitional cell carcinoma of the bladder
and prostate. Cancer. 1993; 71: 3993-4001.
- Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al.:
Radical cystectomy in the treatment of invasive bladder cancer: long-term
results in 1,054 patients. J Clin Oncol. 2001; 19: 666-75.
- Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas
A, et al.: The rationale for en bloc pelvic lymph node dissection for
bladder cancer patients with nodal metastases: long-term results. J
Urol. 1993; 149: 758-64.
- Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF:
Impact of the number of lymph nodes retrieved on outcome in patients
with muscle invasive bladder cancer. J Urol. 2002; 167: 1295-8.
- Lieskovsky G, Skinner DG: Role of lymphadenectomy in the treatment
of bladder cancer. Urol Clin North Am. 1984; 11: 709-16.
- Ariyoshi A, Minoda K, Komatsu K, Fujisawa Y, Yamaguchi A, Yoshida
T: Does ‘extended’ pelvic lymphadenectomy truly contribute
to the management of bladder carcinoma? Eur Urol. 1986; 12: 314-7.
- Herr HW: Bladder cancer: pelvic lymphadenectomy revisited. J Surg
Oncol. 1988; 37: 242-5.
- Wishnow KI, Johnson DE, Ro JY, Swanson DA, Babaian RJ, von Eschenbach
AC: Incidence, extent and location of unsuspected pelvic lymph node
metastasis in patients undergoing radical cystectomy for bladder cancer.
J Urol. 1987; 137: 408-10.
- Vieweg J, Whitmore WF Jr, Herr HW, Sogani PC, Russo P, Sheinfeld
J, et al.: The role of pelvic lymphadenectomy and radical cystectomy
for lymph node positive bladder cancer. The Memorial Sloan-Kettering
Cancer Center experience. Cancer. 1994; 73: 3020-8.
- Turner WH, Markwalder R, Perrig S, Studer UE: Meticulous pelvic lymphadenectomy
in surgical treatment of the invasive bladder cancer: an option or a
must? Eur Urol. 1998; 33: 21-2.
- Leissner J, Hohenfellner R, Thuroff JW, Wolf HK: Lymphadenectomy
in patients with transitional cell carcinoma of the urinary bladder;
significance for staging and prognosis. BJU Int. 2000; 85: 817-23.
- Brossner C, Pycha A, Toth A, Mian C, Kuber W: Does extended lymphadenectomy
increase the morbidity of radical cystectomy? BJU Int. 2004; 93: 64-6.
- Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch
M, et al.: Extended radical lymphadenectomy in patients with urothelial
bladder cancer: results of a prospective multicenter study. J Urol.
2004; 171: 139-44.
- Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP: Stage specific
lymph node metastasis mapping in radical cystectomy specimens. J Urol.
2004; 171: 1830-4.
- Sherif A, De La Torre M, Malmstrom PU, Thorn M: Lymphatic mapping
and detection of sentinel nodes in patients with bladder cancer. J Urol.
2001; 166: 812-5.
- Ghoneim MA, Abol-Enein H: Lymphadenectomy with cystectomy: is it
necessary and what is its extent? Eur Urol. 2004; 46: 457-61.
- Stein JP, Cai J, Groshen S, Skinner DG: Risk factors for patients
with pelvic lymph node metastases following radical cystectomy with
en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol.
2003; 170:35-41.
- Herr HW: Superiority of ratio based lymph node staging for bladder
cancer. J Urol. 2003; 169: 943-5.
- Konety BR, Joslyn SA, O’Donnell MA: Extent of pelvic lymphadenectomy
and its impact on outcome in patients diagnosed with bladder cancer:
analysis of data from the Surveillance, Epidemiology and End Results
Program data base. J Urol. 2003; 169: 946-50.
- Raghavan D: Chemotherapy and cystectomy for invasive transitional
cell carcinoma of bladder. Urol Oncol. 2003; 21: 468-74.
- Shelley MD, Wilt TJ, Barber J, Mason MD: A meta-analysis of randomised
trials suggests a survival benefit for combined radiotherapy and radical
cystectomy compared with radical radiotherapy for invasive bladder cancer:
are these data relevant to modern practice? Clin Oncol (R Coll Radiol).
2004; 16: 166-71.
____________________
Accepted after revision:
July 1, 2006
_______________________
Correspondence address:
Dr. C. W. Cheng
Department of Surgery
The Chinese University of Hong Kong
Prince of Wales Hospital, Hong Kong, China
Fax: + 8 52 2635-9307
E-mail: drmcheng@hotmail.com
EDITORIAL COMMENT
In
this study, the authors have reviewed an experience acquired over the
last fourteen years in the management of bladder cancer by radical cystectomy.
They looked at the usefulness of the lymph node density as the indicator
of prognosis and the disease specific survival. Many factors can influence
the outcome of the patients with bladder cancer including T stage, N stage
and the total number of lymph node retrieved.
A
large number of publications have highlighted the importance of prognostic
factor including age, gender and lymph node status and evidenced that
the number of the involved lymph nodes was the single most important prognostic
variable.
Herr
(1) introduced the term lymph node density indicating the ratio between
the number of nodes removed to the number of nodes involved. They found
that the ration based lymph node staging which reflect the quality of
lymph node dissection was a significant variable prognostic for survival
and local control of patients, which are left with node involvement after
radical cystectomy.
Stein
et al. (2) reported their experience of 244 patients with pathological
lymph node metastases treated for primary carcinoma of the bladder. They
reported that overall and recurrence free survival were significantly
related to the pathological subgroup with the primary bladder tumor. Patients
with lymph node density of 20% or less had better recurrence free survival
when compared to those with more than 20% (statistically significant).
The total number of lymph nodes removed at surgery was also prognostic.
Patients with 15 or less lymph nodes removed had 25% 10-year recurrence-free
survival compared with 36% when greater than 15 lymph nodes were removed.
REFERENCES
1. Herr H: Superiority
of ratio based lymph node staging for bladder cancer. J Urol. 2003; 169:
943-5.
2. Stein JP, Cai J, Groshen S, Skinner DG: Risk factors for patients with
pelvic lymph node metastases following radical cystectomy with en bloc
pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003; 170:
35-41.
Dr. Hammad
M. Ather
Department of Surgery
Aga Khan University Hospital
Karachi, Pakistan
E-mail: hammad.ather@aku.edu
EDITORIAL
COMMENT
The
authors present their experience and clinical outcomes in 133 patients
who underwent radical cystectomy for transitional cell carcinoma over
a 13-year period of time. They found the pT stage and lymph node density
and postoperative adjuvant radiotherapy to distant metastases were predictive
of cancer specific survival. In addition, in those with lymph node positive
disease a 20% lymph node density was an important risk stratifier.
The
authors comment that radical cystectomy can reach good results with organ
confined bladder cancer, which is true, however even those with locally
advanced and with regional lymph node involvement benefit from a surgical
approach with the best reported outcomes.
The
median follow-up is very short and should be noted as potential weakness
of the study.
Dr. John Peter Stein
Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, California, USA
E-mail: stein@hsc.usc.edu
EDITORIAL
COMMENT
The
purpose of the manuscript was to determine the significance of lymph node
density on survival of patients with transitional cell carcinoma of the
bladder undergoing cystectomy. There are now 3 or 4 papers demonstrating
the significance of lymph node density on recurrence and so this is a
relevant paper and topic.
The
study design in the most part supports the conclusion; however, the inclusion
of patients receiving preoperative and postoperative chemotherapy (21
patients) and the 17 patients receiving preoperative or postoperative
radiotherapy to distant metastasis were included.
The
main thrust of the paper was to determine the significance of lymph node
density on survival. Only 11 patients had a lymph node density > 20%,
with 108 presenting lymph node density < 20%. Reaching a conclusion
on these 11 patients is concerning.
In
conclusion, this is an interesting paper and certainly timely with all
the data on the significance of lymph node density.
Dr.
Stephen D. Beck
Department of Urology
Indiana University School of Medicine
Indianapolis, Indiana, USA
E-mail: stdbeck@iupui.edu |